Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q2 2023 · 10-Q
Revenue$595.28M$595.28M+11.5% vs Q2 2022 Net Income$56.04M$56.04M+102.6% vs Q2 2022 EPS Diluted$0.29$0.29+93.3% vs Q2 2022 Operating Income$65,566,000+67.5% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$48,479,000+66.8% Margins · derivedOperating margin11.0%+3.7 pt vs Q2 2022
Net margin9.4%+4.2 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 2, 2023 · 33 d after period end